rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PPH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Which Healthcare ETF Is the Better Buy: VanEck’s Pharma Fund PPH or iShares’ Biotech Fund IBB? | The Motley Fool

      One fund owns the big drugmakers that pay dividends. The other owns the broader biotech field, where stocks swing more. Here is which fits long-term investors.

      Nov 15The Motley FoolIBBPPH
      Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF | The Motley Fool

      VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees.

      Oct 30The Motley FoolPPHSTTDESK
      PPH: Key Pharmaceutical Innovations Support Bullish Outlook (Upgrade)
      Oct 29Seeking AlphaPPH
      Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? | The Motley Fool

      IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.

      Oct 26The Motley FoolPPHDESKIHE
      Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? | The Motley Fool

      VanEck offers lower costs and higher dividends with a concentrated pharma focus, while Simplify provides broader healthcare exposure and donates profits to breast cancer research.

      Oct 11The Motley FoolPPHDESKPINK
      Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP | The Motley Fool

      VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

      Oct 3The Motley FoolPPHIVZDESK
      Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

      Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailPPH
      VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? | The Motley Fool

      PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

      Sep 15The Motley FoolBBHPPHDESK
      Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus | The Motley Fool

      VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.

      Aug 26The Motley FoolPPHFHLC

      This is the newest page. Registered accounts read further back.